



**QUEEN'S
UNIVERSITY
BELFAST**

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer

Yang, L., Roberts, D., Takhar, M., Erho, N., Bibby, B. A. S., Thiruthaneeswaran, N., Bhandari, V., Cheng, W-C., Haider, S., McCorry, A. M. B., McArt, D., Jain, S., Alshalalfa, M., Ross, A., Schaffer, E., Den, R. B., Jeffrey Karnes, R., Klein, E., Hoskin, P. J., ... West, C. M. L. (2018). Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer. *EBioMedicine*, 31, 182-189.
<https://doi.org/10.1016/j.ebiom.2018.04.019>

Published in:
EBioMedicine

Document Version:
Publisher's PDF, also known as Version of record

Queen's University Belfast - Research Portal:
[Link to publication record in Queen's University Belfast Research Portal](#)

Publisher rights

Copyright 2018 the authors.

This is an open access article published under a Creative Commons Attribution-NonCommercial-NoDerivs License (<https://creativecommons.org/licenses/by-nc-nd/4.0/>), which permits distribution and reproduction for non-commercial purposes, provided the author and source are cited.

General rights

Copyright for the publications made accessible via the Queen's University Belfast Research Portal is retained by the author(s) and / or other copyright owners and it is a condition of accessing these publications that users recognise and abide by the legal requirements associated with these rights.

Take down policy

The Research Portal is Queen's institutional repository that provides access to Queen's research output. Every effort has been made to ensure that content in the Research Portal does not infringe any person's rights, or applicable UK laws. If you discover content in the Research Portal that you believe breaches copyright or violates any law, please contact openaccess@qub.ac.uk.



Research Paper

Development and Validation of a 28-gene Hypoxia-related Prognostic Signature for Localized Prostate Cancer



Lingjian Yang^a, Darren Roberts^a, Mandeep Takhar^b, Nicholas Erho^b, Becky A.S. Bibby^a, Niluja Thiruthaneeswaran^{a,p}, Vinayak Bhandari^{c,q}, Wei-Chen Cheng^d, Syed Haider^{d,e}, Amy M.B. McCorry^f, Darragh McArt^f, Suneil Jain^f, Mohammed Alshalalfa^b, Ashley Ross^g, Edward Schaffer^h, Robert B. Denⁱ, R. Jeffrey Karnes^j, Eric Klein^k, Peter J. Hoskin^l, Stephen J. Freedland^m, Alastair D. Lamb^{n,o}, David E. Neal^o, Francesca M. Buffa^{d,e}, Robert G. Bristow^{p,r}, Paul C. Boutros^{c,r}, Elai Davicioni^b, Ananya Choudhury^a, Catharine M.L. West^{a,s,*}

^a Translational Radiobiology Group, Division of Cancer Sciences, University of Manchester, Manchester Academic Health Science Centre, Christie Hospital, Manchester M20 4BX, UK

^b GenomeDx Biosciences, Vancouver, BC, Canada

^c Informatics & Biocomputing Program, Ontario Institute for Cancer Research, Toronto, Canada

^d Department of Oncology, University of Oxford, Oxford OX3 7DQ, UK

^e Weatherall Institute of Molecular Medicine, University of Oxford, Oxford OX3 9DS, UK

^f Centre for Cancer Research and Cell Biology, Queen's University Belfast, Belfast BT9 7BL, Northern Ireland, UK

^g James Buchanan Brady Urological Institute, Johns Hopkins Medical Institutions, Baltimore, MD, USA

^h Northwestern Feinberg School of Medicine, Chicago, IL, USA

ⁱ Department of Radiation Oncology, Sidney Kimmel Medical College at Thomas Jefferson University, Philadelphia, PA, United States

^j Department of Urology, Mayo Clinic Rochester, MN, USA

^k Glickman Urological Institute, Cleveland Clinic, Cleveland, OH, USA

^l Mount Vernon Cancer Centre, Rickmansworth Road, Northwood, Middlesex HA6 2RN, UK

^m Department of Surgery, Division of Urology, Center for Integrated Research on Cancer and Lifestyle, Samuel Oschin Comprehensive Cancer Center, Cedars-Sinai Medical Center, Los Angeles, CA, USA

ⁿ Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge CB2 0RE, UK

^o Nuffield Department of Surgical Sciences, University of Oxford, Old Road Campus Research Building, Headington, Oxford OX3 7DQ, UK

^p Princess Margaret Cancer Centre, University Health Network, Toronto, Canada

^q Sydney Medical School, University of Sydney, Sydney, Australia

^r Department of Medical Biophysics, University of Toronto, Toronto, Ontario, Canada

^s NIHR Manchester Biomedical Research Centre, Central Manchester University Hospitals NHS Foundation Trust, Manchester Academic Health Science Centre, UK

ARTICLE INFO

Article history:

Received 5 March 2018

Received in revised form 11 April 2018

Accepted 20 April 2018

Available online 23 April 2018

Keywords:

Gene expression signature

Hypoxia

Prognostic biomarker

Prostate cancer

Radiotherapy

ABSTRACT

Background: Hypoxia is associated with a poor prognosis in prostate cancer. This work aimed to derive and validate a hypoxia-related mRNA signature for localized prostate cancer.

Method: Hypoxia genes were identified *in vitro* via RNA-sequencing and combined with *in vivo* gene co-expression analysis to generate a signature. The signature was independently validated in eleven prostate cancer cohorts and a bladder cancer phase III randomized trial of radiotherapy alone or with carbogen and nicotinamide (CON).

Results: A 28-gene signature was derived. Patients with high signature scores had poorer biochemical recurrence free survivals in six of eight independent cohorts of prostatectomy-treated patients (Log rank test $P < .05$), with borderline significances achieved in the other two ($P < .1$). The signature also predicted biochemical recurrence in patients receiving post-prostatectomy radiotherapy ($n = 130$, $P = .007$) or definitive radiotherapy alone ($n = 248$, $P = .035$). Lastly, the signature predicted metastasis events in a pooled cohort ($n = 631$, $P = .002$). Prognostic significance remained after adjusting for clinic-pathological factors and commercially available prognostic signatures. The signature predicted benefit from hypoxia-modifying therapy in bladder cancer patients (intervention-by-signature interaction test $P = .0026$), where carbogen and nicotinamide was associated with improved survival only in hypoxic tumours.

* Corresponding author at: Translational Radiobiology Group, University of Manchester, Manchester Academic Health Centre, Christie Hospital, Wilmslow Road, Manchester M20 4BX, UK.

E-mail address: catharine.west@manchester.ac.uk (C.M.L. West).

Conclusion: A 28-gene hypoxia signature has strong and independent prognostic value for prostate cancer patients.

© 2018 Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

1. Introduction

Ninety percent of prostate cancer (PCa) patients are diagnosed with localized carcinoma, which have a highly variable course of disease progression. Hypoxia is a common micro-environmental feature in most solid tumours, which leads to changes in transcriptomic profiles, a higher potential to metastasise and resistance to radiotherapy [1]. Localized prostate cancer has marked and heterogeneous hypoxia [2], and hypoxia is an adverse prognostic feature [3–5]. Combining hypoxia-targeting treatment with radiotherapy was shown to improve local control of tumours and survival of patients in head and neck and bladder cancers [6–9]. There is good evidence from the literature that the most hypoxic tumours benefit the most from hypoxia-modifying therapy. However, there is no clinically validated method of selecting prostate cancer patients who would benefit from hypoxia modifying treatment.

Hypoxia gene signatures were successfully derived for multiple tumour sites including head and neck, bladder, soft tissue sarcoma and cervical cancers, which were not only independently prognostic but also predictive of benefit from hypoxia-modifying therapy in head and neck and bladder cancers [10–18]. Work in prostate cancer showed some prognostic significance for signatures derived in other tumour types [3] or associated with the hypoxia marker pimonidazole [15].

We previously showed that hypoxia gene signatures are better if tumour site specific [19]. The aim of this study was to generate and validate a prostate cancer-specific transcriptomic signature. *In vitro* analysis of genes regulated by hypoxia was combined with *in vivo* analysis of a gene co-expression network and patient survival using data from a retrospective cohort. Following signature derivation, validation was performed in multiple independent cohorts.

2. Methods

2.1. Patient Cohorts

This study included patients with prostate carcinoma from twelve cohorts, including the cancer genome atlas project (TCGA) [20], GSE54460 [21], GSE21032 [22], CPC-GENE [23], Cambridge [24,25], six retrieved from the Decipher GRID™ prostate cancer database (NCT02609269) [26–31], and one from Belfast [32]. A summary of the cohorts and procedures for pre-processing of transcriptomic data are provided in Supplementary Table 1 and Supplementary Methods. Patient cohort characteristics are summarised in Supplementary Table 2. The TCGA cohort was used as the training cohort. In addition, bladder cancer patients enrolled in a randomized trial of hypoxia-modifying therapy were available in the BCON cohort [6,18]. Informed consent protocols were approved by local Institutional Review Boards.

2.2. Endpoints and Statistical Analysis

Biochemical recurrence (BCR) free survival was the clinical endpoint of this study in all but one cohort. Distant metastasis (DMET) free survival was the clinical endpoint of the other cohort. Patient follow up data were censored at 5-year. The signature derived from this work assigned one hypoxia signature score for each individual tumour and in each cohort patients were stratified into high vs. low hypoxia based on the median cohort signature score. Survival estimates were performed using the Kaplan-Meier method. The Log-rank test was used to test the null hypothesis of equality of survival distributions. Hazard ratios (HR) and 95% confidence intervals (CI) were obtained using the

Cox proportional hazard model. In case-cohort studies (originally designed to sample the adverse pathology population to estimate risk of metastasis after radical prostatectomy), randomly sampled sub-cohorts were used in order to reduce over-estimation of events in evaluation of the BCR endpoint. Odds ratios (OR) were obtained using logistic regression models. Association between hypoxia signature score and Gleason group, tumour stage was estimated using simple linear regression. All *P*-values were two sided and statistical significance was set as 0.05.

2.3. Prostate Cancer Hypoxia Signature Development

A network-based methodology was applied for generation of a prostate cancer-specific hypoxia signature, hypothesising that *in vitro* hypoxia regulated genes co-expressing with each other *in vivo* collectively indicate tumour hypoxia. Briefly, genes up- and down-regulated by hypoxia (1% O₂, 24 h) were identified with RNA sequencing in four PCa cell lines (PNT2-C2, LNCaP, DU-145, and PC-3). The four cell lines were chosen as they were derived from human tissues and are widely used as *in vitro* PCa models [33]. A gene co-expression network was constructed in a TCGA training cohort and a putative gene module enriched with *in vitro* hypoxia genes was identified. Genes within the putative module were ranked by their connectivity and added iteratively into the signature. The final signature was selected based on prognostic significance. The signature scores are a continuous variable, which were then binarised into high and low categories using the median value for each cohort. The hypoxia signature derived here was then independently validated in the other eleven PCa cohorts. In multivariable analysis, the hypoxia gene signature was adjusted for standard clinic-pathological factors and a genomic classifier Decipher [27]. More details were given in Supplementary Methods.

2.4. Comparison with Literature Transcriptomic and Genomic Signatures

Seven hypoxia [10,11,14–17] and eleven prostate cancer transcriptomic signatures [34–44] were curated from the literature and their prognostic significances were evaluated for comparison (Supplementary methods). Furthermore, the potential benefit of combining the *de novo* hypoxia signature with a prognostic 31-loci DNA classifier [45] was also investigated by entering both into a Cox model.

3. Results

3.1. In Vitro Hypoxia Responsive Genes

Genes up or down regulated under hypoxia in four PCa cell lines were identified. 84, 306 and 848 genes were differentially expressed in greater than four, three and two cell lines, respectively. A seed gene database was constructed consisting of the 848 genes differentially expressed in two or more cell lines (Supplementary Table 3). Eight cell cycle and metabolism pathways were enriched in the hypoxia seed gene dataset (Supplementary Table 4). For many of the above identified genes, their regulation under hypoxia was well documented [46,47].

3.2. In Vivo Prostate Cancer-specific Hypoxia Gene Module

A PCa gene co-expression network was built from pre-treatment tumour biopsies in the TCGA cohort. The network, containing 1856 genes (including 113 seed genes) of good variability was partitioned into 34

gene modules. One module of 66 genes was identified most hypoxia-related as 33% of its member genes ($22/66$, $P = 4.85 \times 10^{-12}$, Supplementary Fig. 1) were seed genes. Another 24 genes from the 66-gene module were hypoxia regulated in one cell line (Supplementary Fig. 2). The final signature, containing 28 genes from the 66-gene module, was derived by evaluating prognostic significance in cross validation. The signature gene coefficients were determined from a Cox survival model (Supplementary Table 5). Patients with high signature scores

were associated with significantly poorer outcome (log rank $P = 1.9 \times 10^{-8}$, Supplementary Fig. 3).

3.3. 28-Gene Signature Is Prognostic of BCR in PCa Cohorts Receiving Radical Prostatectomy

The high correlation among the 28 hypoxia signature genes was well preserved in the independent validation cohorts (Supplementary Fig.




Fig. 1. Kaplan-Meier or receiver operating characteristic plots for independent validation of the 28-gene hypoxia signature in prostatectomy-treated cohorts.

4), suggesting the good reproducibility of the signature. The 28 signature genes also clustered tumours in independent validation cohorts into two clear groups (Supplementary Figs. 5 and 6).

The 28-gene signature and all coefficients were frozen and applied to independent validation cohorts. The prognostic value of the 28-gene hypoxia signature was first validated in the GSE21032 (fresh frozen), GSE54460 (FFPE) and Cambridge (fresh frozen) prostatectomy cohorts. In both GSE21032 and GSE54460, tumours with high 28-gene signature scores were associated with significantly poorer 5-year BCR in the GSE21032 ($n = 131$, HR 4.59, 95% CI 1.71–12.32, $P = .0025$, Fig. 1A) and GSE54460 ($n = 106$, HR 2.12, 95% CI 1.20–3.74, $P = .0098$, Fig. 1B) cohorts. In the Cambridge cohort, borderline prognostic significance was observed with the default median cut-off signature score ($n = 111$, HR 2.54, 95% CI 0.96–6.69, $P = .06$, Fig. 1C), which improved when an upper quartile split was used (HR 4.54, 95% CI 1.82–11.36, $P = .0011$). A continuous 28-gene signature score also achieved prognostic significance ($P = .047$) in the Cambridge cohort.

In other five prostatectomy-treated cohorts, tumours with high 28-gene signature scores were again associated with significantly poorer outcome (GSE79957: $n = 260$, HR 1.60, $P = .055$; GSE62116: $n = 235$, HR 2.04 $P = .007$; GSE41408: $n = 48$, OR 7.60, $P = .0022$; GSE62667: $n = 182$, OR 5.90, $P = .000036$; and CPC-GENE: $n = 212$, HR 1.80, $P = .026$, Fig. 1D to H).

Multivariable analysis was performed adjusting the hypoxia signature with clinicopathological covariates and the Decipher genomic classifier, wherever possible (Table 1). Statistical significance was retained in three cohorts (GSE21032: HR 3.51, $P = .021$; GSE54460: HR 1.84, $P = .048$; and CPC-GENE: HR 1.81, $P = .021$), and was borderline in another two cohorts (GSE62116: HR 1.36, $P = .059$; and GSE41408: OR 2.89, $P = .081$).

3.4. 28-Gene Signature is a Strong Independent Prognostic Factor in PCa Cohorts Receiving Radiotherapy

The 28-gene signature predicted biochemical recurrence in the GSE72291 cohort treated with post-operative radiotherapy ($n = 130$, HR 2.81, 95% CI 1.33–6.00, $P = .007$, Fig. 2A). In multivariable analysis (Table 2), the hypoxia signature remained a strong prognostic factor (HR = 2.17, $P = .014$) alongside Decipher (HR 2.24, $P = .0061$), Gleason group 5 (HR 8.50, $P = .0012$), and pre-treatment PSA level (HR 1.74, $P = .0042$). The hypoxia signature was also prognostic in the Belfast cohort of intermediate/high-risk patients who underwent definitive radiotherapy ($n = 248$, log rank $P = .035$, Fig. 2B). Multivariable analysis was not performed due to the low event rate.

3.5. 28-Gene Signature Predicts Metastatic Outcome

The 28-gene signature was also evaluated in a pooled cohort of 631 PCa patients from four studies with metastatic outcome [29–31,48]. The signature predicted distant metastasis events with a HR of 2.41 (95% CI 1.38–4.19, $P = .002$). In multivariable analysis, the hypoxia signature remained significant (HR 2.57, 95% CI 1.38–4.77, $P = .003$) alongside Decipher, seminal vesicle invasion and lymph node invasion (Table 3).

3.6. 28-Gene Signature Is Associated With Gleason Score and Tumour Stage

A positive and significant correlation was seen between the 28-gene signature score and pathological Gleason score in five of the six examined cohorts (Supplementary Fig. 7). Hypoxia score increased significantly with tumour stage in four of the six cohorts (Supplementary Fig. 8), but was not associated with pre-treatment PSA (Supplementary Fig. 9). In GSE21032, the hypoxia signature scores were significantly higher in metastatic compared with primary tissue ($P = .007$, Supplementary Fig. 10).

Table 1

Multivariable analysis of the 28-gene hypoxia signature in independent cohorts of PCa patients receiving radical prostatectomy.

Study	Variable	Multivariable analysis	
Cohort and case-cohort studies		HR (95% CI)	P-value
GSE21032	Hypoxia	3.51 (1.21–10.15)	.021
	Gleason Group 2 VS 1	0.69 (0.20–2.47)	.57
	Gleason Group 3 VS 1	4.12 (1.32–12.91)	.0015
	Gleason Group ≥ 4 VS 1	2.45 (0.72–8.31)	.15
	Log2 pre-treatment PSA	1.04 (0.64–1.69)	.88
	SVI	3.86 (1.25–11.92)	.019
	SM	1.44 (0.55–3.74)	.46
	ECE	2.58 (0.70–9.52)	.155
	Hypoxia	1.84 (1.00–3.39)	.048
	Gleason Group 2 VS 1	1.49 (0.42–5.34)	.54
GSE54460	Gleason Group 3 VS 1	2.77 (0.76–10.13)	.123
	Gleason Group 4 VS 1	2.21 (0.45–10.74)	.33
	Gleason Group 5 VS 1	2.33 (0.50–10.83)	.28
	Log2 pre-treatment PSA	1.74 (1.21–2.50)	.0029
	Clinical T Stage 2 VS 1	0.47 (0.22–1.01)	.052
	Clinical T Stage ≥ 3 VS 1	0.62 (0.23–1.62)	.33
	SM	2.47 (1.35–4.55)	.0035
	Hypoxia	1.53 (0.54–4.30)	.42
	Gleason Group 2 VS 1	1.84 (0.20–17.28)	.59
	Gleason Group 3 VS 1	8.27 (0.79–86.99)	.078
Cambridge	Gleason Group 4 VS 1	15.66 (1.36–181.00)	.028
	Gleason Group 5 VS 1	490.3 (11.7–20,542.2)	.0011
	Log2 pre-treatment PSA	0.54 (0.22–1.37)	.19
	SM	1.32 (0.46–3.76)	.61
	ECE	1.42 (0.42–4.72)	.57
	Hypoxia	1.81 (1.02–3.21)	.021
	Gleason Group 2 VS 1	0.85 (0.35–2.05)	.68
	Gleason Group 3 VS 1	0.82 (0.31–2.20)	.65
	Gleason Group ≥ 4 VS 1	3.00 (0.27–33.85)	.310
	Pre-treatment PSA	1.04 (0.98–1.11)	.152
CPC-GENE	Clinical T Stage 2 VS 1	1.80 (1.03–3.13)	.018
	Hypoxia	1.36 (0.99–1.88)	.059
	Decipher	1.15 (0.86–1.53)	.36
	Gleason Group 3 VS ≤ 2	2.21 (1.10–4.40)	.026
	Gleason Group 4 VS ≤ 2	1.29 (0.57–2.93)	.54
	Gleason Group 5 VS ≤ 2	1.13 (0.53–2.44)	.75
	Log2 pre-treatment PSA	1.21 (0.96–1.52)	.10
	SVI	0.87 (0.46–1.66)	.68
	SM	1.67 (0.95–2.95)	.076
	ECE	1.83 (1.01–3.31)	.046
GSE62116	LNI	0.73 (0.31–1.74)	.48
	Hypoxia	0.93 (0.58–1.48)	.76
	Decipher	1.58 (1.11–2.23)	.010
	Gleason Group 3 VS ≤ 2	0.84 (0.33–2.17)	.72
	Gleason Group 4 VS ≤ 2	1.32 (0.46–3.82)	.61
	Gleason Group 5 VS ≤ 2	2.46 (1.20–5.03)	.014
	Log2 pre-treatment PSA	1.25 (0.94–1.66)	.122
	SVI	1.57 (0.82–3.03)	.180
	SM	1.96 (0.99–3.88)	.052
	ECE	2.18 (0.85–5.60)	.104
GSE79957	LNI	4.71 (2.43–9.14)	<.001
Case control studies		OR (95% CI)	P-value
GSE62667	Hypoxia	1.19 (0.62–2.30)	.61
	Decipher	2.26 (1.28–4.23)	.0069
	Gleason Group 3 VS ≤ 2	1.77 (0.47–6.38)	.39
	Gleason Group 4 VS ≤ 2	2.03 (0.43–8.98)	.36
	Gleason Group 5 VS ≤ 2	8.68 (1.94–42.91)	.0057
	Log2 pre-treatment PSA	1.56 (0.97–2.57)	.071
	SVI	2.70 (0.81–8.99)	.103
	SM	2.20 (0.80–6.39)	.133
	ECE	3.99 (1.01–20.55)	.067
	Hypoxia	2.89 (0.94–10.79)	.081
GSE41408	Decipher	0.41 (0.089–1.66)	.22
	Gleason Group 3 VS ≤ 2	1 (0–NA)	.99
	Gleason Group ≥ 4 VS ≤ 2	3.94 (0.29–67.75)	.31
	Log2 pre-treatment PSA	3.02 (1.29–9.55)	.031

PSA: prostate specific antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE: extracapsular extension; LNI: lymph node invasion.




Fig. 2. Kaplan-Meier plots for independent validation of the 28-gene hypoxia signature in A) post-prostatectomy radiotherapy cohort; B) radiotherapy-treated cohort.

3.7. Prediction of Benefit from Hypoxia Modification of Radiotherapy

The 28-gene prostate signature was further validated in the BCON phase III randomized trial of radiotherapy alone or with carbogen and nicotinamide (CON) for bladder cancer patients. Tumours were stratified as high or low from median, first, and third quartiles of cohort 28-gene signature scores. When the first quartile was used, high hypoxic tumours were associated with a non-significant trend of poor prognosis in patients treated with radiotherapy only (overall survival, $n = 75$, HR 1.68, $P = .17$, Supplementary Fig. 11). BCON tumours stratified as high hypoxic had improved survival with the addition of CON ($n = 113$, HR 0.54, 95% CI 0.32–0.91, $P = .021$). For low-hypoxic tumours, giving CON with RT was associated with poorer survival ($n = 38$, HR 2.49, 95% CI 1.06–5.89, $P = .037$, Supplementary Fig. 12). A signature-intervention interaction test confirmed the predictive value of the signature for both binary hypoxic status ($P = .0026$) and continuous hypoxia score ($P = .037$). CON was shown to have a detrimental effect on the 25% BCON patients with low 28-gene signature scores. As one given treatment would only benefit a subset of patients and might even produce adverse effect on others, this emphasized the importance of identifying reliable predictive biomarker.

3.8. Comparison with Literature Gene Signatures

The prognostic value of published hypoxia and PCa transcriptomic signatures were compared in both GSE21032 and GSE54460 (Supplementary Tables 6 and 7). One PCa hypoxia signature [15] reached

(borderline) prognostic significance in both cohorts. The Toustrup signature [16], derived for head and neck cancer, was prognostic in both cohorts. Our 28-gene signature scores correlated moderately with Toustrup signature scores (GSE21032: Pearson $r = 0.33$, $P = .00011$; GSE54460: Pearson $r = 0.51$, $P = 2.32 \times 10^{-8}$, Supplementary Fig. 13). The 28-gene signature had higher prognostic significance and was the only significant factor when both signatures were entered into a Cox proportional hazards regression model (Supplementary Table 8).

3.9. Association with Copy Number Alteration Burden and Genomic Classifier

Recent studies suggested global copy number alteration (CNA) burden as a prognostic marker of PCa patients [22,49]. A very moderate correlation was found between global CNA burden, defined as the percentage of the tumour genome affected by CNA, and hypoxia signature scores for both TCGA (Pearson correlation 0.36, Supplementary Fig. 14) and GSE21032 (Pearson correlation 0.40, Supplementary Fig. 14). Hypoxia signature (binary or continuous) and CNA burden (continuous) both retained significance when entered together into a Cox model in both cohorts (Supplementary Tables 9 and 10).

A 100-loci prognostic classifier for localized PCa [3] was recently identified and reduced to a 31-loci signature [45]. Both reflect genomic instability and were shown to have high prognostic value in >500 prostate cancer patients. We examined if adding the 28-gene signature and genomic classifier could further improve prognostication for PCa

Table 2

Multivariable analysis of the 28-gene signature in predicting biochemical recurrence in patients receiving radical prostatectomy and adjuvant radiotherapy.

Study	Variable	Multivariable analysis	
GSE72291	Hypoxia	2.17 (1.17–4.01)	0.014
	Decipher	2.24 (1.26–4.00)	0.0061
	Gleason Group 3 VS ≤ 2	2.49 (0.72–8.56)	0.148
	Gleason Group 4 VS ≤ 2	2.34 (0.67–8.21)	0.183
	Gleason Group 5 VS ≤ 2	8.50 (2.34–30.92)	0.0012
	Log2 pre-treatment PSA	1.74 (1.19–2.55)	0.0042
	SVI	1.21 (0.51–2.85)	0.66
	SM	0.60 (0.25–1.49)	0.27
	ECE	3.15 (0.89–11.17)	0.075

PSA: prostate specific antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE: extracapsular extension; LNI: lymph node invasion.

Table 3

Multivariable analysis of the 28-gene signature in predicting metastatic outcome.

Study	Variable	Multivariable analysis	
Pooled cohort	Hypoxia	2.57 (1.38–4.77)	0.003
	Decipher	1.22 (1.06–1.41)	0.007
	Gleason Group 2 VS 1	1.13 (0.14–9.30)	0.907
	Gleason Group 3 VS 1	3.50 (0.43–28.26)	0.239
	Gleason Group 4 VS 1	3.67 (0.45–30.06)	0.226
	Gleason Group 5 VS 1	5.83 (0.74–45.96)	0.094
	Log2 pre-treatment PSA	1.02 (0.79–1.33)	0.864
	AGE	0.99 (0.95–1.03)	0.522
	SVI	2.01 (1.15–3.51)	0.014
	SM	1.45 (0.84–2.51)	0.18
	ECE	1.39 (0.70–2.75)	0.346
	LNI	1.95 (1.04–3.67)	0.037

PSA: prostate specific antigen; SVI: seminal vesicle invasion; SM: surgical margin; ECE: extracapsular extension; LNI: lymph node invasion.

patients. In the CPC-GENE cohort [23], the 28-gene signature (log rank $P = .023$, Fig. 1F) achieved similar prognostic significance compared with the 31-loci genomic instability classifier (log rank $P = .042$, Supplementary Fig. 15). Combining the 31-loci genomic classifier with the 28-gene signature improved prognostication (log rank $P = .0035$, Supplementary Fig. 16). Using patients with low 28-gene signature and low 31-loci signature as a reference, patients with high 28-gene signature and high 31-loci signature had a significantly poorer outcome (HR 2.75, 95% CI 1.42–5.31, $P = .0026$). Patients with only positive 28-gene signature ($P = .58$) or 31-loci signature ($P = .41$) had similar survival as the double negative group, respectively (Supplementary Table 11). The above analyses suggested that improved prognostication can be achieved by combining the 28-gene signature and indicators of genome instability, consistent with the previous observation from Lalonde et al. [3].

4. Discussion

A 28-gene signature was derived and shown to be independently prognostic in eleven cohorts of low- to high-risk prostate cancer patients with localized disease. Ten genes (*ATF3*, *BHLHE40*, *SLC2A3*, *EGR1*, *KLF10*, *FOSL2*, *CYR61*, *SLC2A14*, *KLF6*, and *TIPARP*) in the 28-gene signature were previously shown to be hypoxia regulated in different tumour sites (Supplementary Table 12). The study showed that the Toustrup hypoxia signature [16], prognostic and predictive of hypoxia-modifying therapy for head and neck cancer, was prognostic in prostate cancer patients. The Ragnum signature [15], the only prostate cancer-specific hypoxia signature in the literature, had (borderline) prognostic significance for biochemical recurrence. A moderate correlation was found between the Toustrup 15-gene and our 28-gene hypoxia signatures score. The derived 28-gene signature could be combined with a recently published genomic classifier to identify a group of high-risk PCa patients with very poor prognosis. The 28-gene hypoxia signature has translational significance. The prognostic value of the signature was independently validated in seven cohorts of biopsies preserved in FFPE blocks, a routine technique for preserving tissues in hospitals. Degradation and chemical modification of nucleic acids in FFPE samples significantly reduces RNA quality. [50] The prognostic significance of the signature was also confirmed using three major high-throughput expression profiling platforms, i.e. Affymetrix array, Illumina BeadArray and RNA-seq. The results of the current study clearly indicate the robustness of the signature for routine clinical application.

One major limitation for the derived 28-gene signature is the lack of benchmarking against gold-standard hypoxia measurement with plographic needle oxygen electrodes. Prognostic information was used in the signature derivation procedure, therefore the final signature could reflect other poor prognostic parameters beyond hypoxia. Use of needle electrode presents great technical challenge, where to date the Toustrup [16] is the only gene expression biomarker that reflected oxygen partial pressure in human tissue. Ragum [15] derived a prostate hypoxia signature based on pimonidazole staining, another approach for assessing tumour hypoxia.

In this study, 1% oxygen concentration was chosen for in vitro experiment as it is widely used in the literature and protein expression of HIF, a major regulator of transcriptional responses to hypoxia, stabilizes in cell lines around this oxygen concentration. One limitation is that certain transcriptional program, for example unfolded protein response genes [51] which are generally activated in oxygen level $\leq 0.2\%$, might be missed. Furthermore, previous research suggested that prostate tumours were profoundly hypoxic with a median oxygen concentration of $\sim 0.5\%$ [52]. Therefore, the signature derived here could be further refined in future studies by adding genes regulated at even lower oxygen concentration.

Another limitation is that the 28-gene signature was prospectively validated in retrospective cohorts, where no standardisation could be achieved in terms of tissue handling, RNA extraction, the amount of

tumour material, etc. However, the prognostic significance was clearly validated, showing a good level of signature robustness. Other limitations include the inability to validate the signature in a prostate cancer phase III trial involving hypoxia modification with both gene expression data and patient outcome. The 28-gene prostate signature was predictive of hypoxia modification therapy for bladder cancer – the only hypoxia modification trial available with full gene expression data. Use of a median score as a cut-off might not be optimal but was chosen as a pre-determined threshold to avoid bias and to provide balanced groups. Also, a median cut-off was used for our head and neck and bladder signatures. Different thresholds were used for different hypoxia signatures and arrays [16,53], and there is no consensus on the ideal method to define tumours as hypoxic and no methodological study exists to date assessing and comparing the performance of the different methods. In a prospective clinical trial the first ~ 50 patient samples could be used to generate a median threshold in newer FFPE blocks for classification.

The 28-gene signature might be further reduced while achieving comparable or slightly worse but acceptable prognostic value. Identifying the minimum set of genes for a signature is a very open research problem. The enormous number of unique combinations of 28 genes definitely opens the door for potential reduction of the signature.

In conclusion, a hypoxia gene signature for primary prostate tumours was derived. Employed as a potential tool for personalized medicine, the signature identifies that more hypoxic tumours have poorer outcome. The signature warrants final qualification in a prospective 28-gene signature-driven randomized trial of hypoxia-modifying therapy.

Conflict of Interest

MT, NE, MA, and ED are employees of GenomeDx Biosciences. RJK received research grant and royalties from GenomeDX.

Author Contribution

Bioinformatics: LY, MT, NE, VB, WCC, SH, AMBM, DM, MA.

Cell line work: DR, BASB, NT.

Result interpretation: LY, DR, MT, NE, VB, WCC, SH, FMB, RBD, AC, CMLW.

Provide data access: AR, ES, RBD, RJK, EK, PJH, SJ, SJF, ADL, DEN, RGB, PCB, ED.

Manuscript preparation: LY, MT, WCC, MA, FMB, PCB, AC, CMLW.

Design of methodology: LY, FMB, AC, CMLW.

Project supervision: DEN, RGB, PCB, ED, AC, CMLW.

All authors approved the final version of the manuscript.

Acknowledgement

Belfast-Manchester Movember Centre of Excellence (CE013_2-004), funded in partnership with Prostate Cancer UK (PG14 008 TR2). Cancer Research UK Major Centre funding. Cancer Research UK Manchester Institute Cancer Research Molecular Biology Core Facility and the University of Manchester Clinical Immune and Molecular Monitoring Laboratory for use of Good Clinical Practice facilities. Medical Research Council of the UK (grant G0801525). Cancer Research UK (grant C2094/A11365). Experimental Cancer Medicine Centre funding. CIHR New Investigator Award, TFRI New Investigator Award, CIHR Graduate Fellowship, Prostate Cancer Canada and the Movember Foundation (Grant RS2014-01). Cancer Research UK (grant 23969) and Oxford MRC/CRUK Institute. The work was supported by researchers at the NIHR Manchester Biomedical Research Centre. The funding sources have no roles in writing or decision or submit it for publication.

Appendix A. Supplementary Data

Supplementary data to this article can be found online at <https://doi.org/10.1016/j.ebiom.2018.04.019>.

References

- Hill, R.P., Bristow, R.G., Fyles, A., Koritzinsky, M., Milosevic, M., Wouters, B.G., 2015]. Hypoxia and predicting radiation response. *Semin Radiat Oncol* 25, 260–272.
- Parker, C., Milosevic, M., Toi, A., Sweet, J., Panzarella, T., Bristow, R., et al., 2004]. Polarographic electrode study of tumor oxygenation in clinically localized prostate cancer. *Int J Radiat Oncol Biol Phys* 58, 750–757.
- Lalonde, E., Ishkanian, A.S., Sykes, J., Fraser, M., Ross-Adams, H., Erho, N., et al., 2014]. Tumour genomic and microenvironmental heterogeneity for integrated prediction of 5-year biochemical recurrence of prostate cancer: a retrospective cohort study. *Lancet Oncol* 15, 1521–1532.
- Milosevic, M., Warde, P., Ménard, C., Chung, P., Toi, A., Ishkanian, A., et al., 2012]. Tumor hypoxia predicts biochemical failure following radiotherapy for clinically localized prostate cancer. *Clin Cancer Res* 18, 2108–2114.
- Turaka, A., Buyyounouski, M.K., Hanlon, A.L., Horwitz, E.M., Greenberg, R.E., Movsas, B., 2012]. Hypoxic prostate/Muscle Po₂</sub> ratio predicts for outcome in patients with localized prostate cancer: long-term results. *Int J Radiat Oncol Biol Phys* 82, e433–e439.
- Hoskin, P.J., Rojas, A.M., Bentzen, S.M., Saunders, M.J., 2010]. Radiotherapy with concurrent carbogen and nicotinamide in bladder carcinoma. *J Clin Oncol* 28, 4912–4918.
- Janssens, G.O., Rademakers, S.E., Terhaard, C.H., Doornaert, P.A., Bijl, H.P., Ende, P.V. D., et al., 2012]. Accelerated radiotherapy with carbogen and nicotinamide for laryngeal cancer: results of a phase III randomized trial. *J Clin Oncol* 30, 1777–1783.
- Overgaard, J., 2011]. Hypoxic modification of radiotherapy in squamous cell carcinoma of the head and neck – a systematic review and meta-analysis. *Radiother Oncol* 100, 22–32.
- Overgaard, J., Sand Hansen, H., Overgaard, M., Bastholt, L., Berthelsen, A., Specht, L., et al., 1998]. A randomized double-blind phase III study of nimorazole as a hypoxic radiosensitizer of primary radiotherapy in supraglottic larynx and pharynx carcinoma. Results of the Danish Head and Neck Cancer Study (DAHANCA) Protocol 5-85. *Radiother Oncol* 46, 135–146.
- Betts, G.N.J., Eustace, A., Patiar, S., Valentine, H.R., Irlam, J., Ramachandran, A., et al., 2013]. Prospective technical validation and assessment of intra-tumour heterogeneity of a low density array hypoxia gene profile in head and neck squamous cell carcinoma. *Eur J Cancer* 49, 156–165.
- Buffa, F.M., Harris, A.L., West, C.M., Miller, C.J., 2010]. Large meta-analysis of multiple cancers reveals a common, compact and highly prognostic hypoxia metagene. *Br J Cancer* 102, 428–435.
- Eustace, A., Mani, N., Span, P.N., Irlam, J.J., Taylor, J., Betts, G.N.J., et al., 2013]. A 26-gene hypoxia signature predicts benefit from hypoxia-modifying therapy in laryngeal cancer but not bladder cancer. *Clin Cancer Res* 19, 4879–4888.
- Fjeldbo, C.S., Julin, C.H., Lando, M., Forsberg, M.F., Aarnes, E.-K., Alnsner, J., et al., 2016]. Integrative analysis of DCE-MRI and gene expression profiles in construction of a gene classifier for assessment of hypoxia-related risk of chemoradiotherapy failure in cervical cancer. *Clin Cancer Res* 22, 4067–4076.
- Lendahl, U., Lee, K.L., Yang, H., Poellinger, L., 2009]. Generating specificity and diversity in the transcriptional response to hypoxia. *Nat Rev Genet* 10, 821–832.
- Ragnum, H.B., Vlatkovic, L., Lie, A.K., Axcrone, K., Julin, C.H., Frikstad, K.M., et al., 2015]. The tumour hypoxia marker pimonidazole reflects a transcriptional programme associated with aggressive prostate cancer. *Br J Cancer* 112, 382–390.
- Toustrup, K., Sørensen, B.S., Nordmark, M., Busk, M., Wiuf, C., Alnsner, J., et al., 2011]. Development of a hypoxia gene expression classifier with predictive impact for hypoxic modification of radiotherapy in head and neck cancer. *Cancer Res* 71, 5923–5931.
- Winter, S.C., Buffa, F.M., Silva, P., Miller, C., Valentine, H.R., Turley, H., et al., 2007]. Relation of a hypoxia metagene derived from head and neck cancer to prognosis of multiple cancers. *Cancer Res* 67, 3441–3449.
- Yang, L., Taylor, J., Eustace, A., Irlam, J., Denley, H., Hoskin, P.J., et al., 2017]. A gene signature for selecting benefit from hypoxia modification of radiotherapy for high risk bladder cancer patients. *Clin Cancer Res* 23, 4761–4768.
- Harris, B.H.L., Barberis, A., West, C.M.L., Buffa, F.M., 2015]. Gene expression signatures as biomarkers of tumour hypoxia. *Clin Oncol* 27, 547–560.
- Abeshouse, A., Ahn, J., Akbani, R., Ally, A., Amin, S., Andry, Christopher D., et al., 2015]. The molecular taxonomy of primary prostate cancer. *Cell* 163, 1011–1025.
- Long, Q., Xu, J., Osunkoya, A.O., Sannigrahi, S., Johnson, B.A., Zhou, W., et al., 2014]. Global transcriptome analysis of formalin-fixed prostate cancer specimens identifies biomarkers of disease recurrence. *Cancer Res* 74, 3228–3237.
- Taylor, B.S., Schultz, N., Hieronymus, H., Gopalan, A., Xiao, Y., Carver, B.S., et al., 2010]. Integrative genomic profiling of human prostate cancer. *Cancer Cell* 18, 11–22.
- Fraser, M., Sabelnykova, V.Y., Yamaguchi, T.N., Heisler, L.E., Livingstone, J., Huang, V., et al., 2017]. Genomic hallmarks of localized, non-indolent prostate cancer. *Nature* 541, 359–364.
- Dunning, M.J., Vowler, S.L., Lalonde, E., Ross-Adams, H., Boutros, P., Mills, I.G., et al., 2017]. Mining human prostate cancer datasets: the camcApp shiny app. *EBioMedicine* 17, 5–6.
- Ross-Adams, H., Lamb, A.D., Dunning, M.J., Halim, S., Lindberg, J., Massie, C.M., et al., 2015]. Integration of copy number and transcriptomics provides risk stratification in prostate cancer: a discovery and validation cohort study. *EBioMedicine* 2, 1133–1144.
- Boormans, J.L., Korsten, H., Ziel-van der Made, A.J.C., van Leenders, G.J.L.H., de Vos, C. V., Jenster, G., et al., 2013]. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. *Int J Cancer* 133, 335–345.
- Erho, N., Crisan, A., Vergara, I.A., Mitra, A.P., Ghadessi, M., Buerki, C., et al., 2013]. Discovery and validation of a prostate cancer genomic classifier that predicts early metastasis following radical prostatectomy. *PLoS One* 8, e66855.
- Freedland, S.J., Choeurng, V., Howard, L., De Hoedt, A., Du Plessis, M., Yousefi, K., et al., 2016]. Utilization of a genomic classifier for prediction of metastasis following salvage radiation therapy after radical prostatectomy. *Eur Urol* 70, 588–596.
- Karnes, R.J., Bergstralh, E.J., Davicioni, E., Ghadessi, M., Buerki, C., Mitra, A.P., et al., 2013]. Validation of a genomic classifier that predicts metastasis following radical prostatectomy in an at risk patient population. *J Urol* 190, 2047–2053.
- Ross, A.E., Johnson, M.H., Yousefi, K., Davicioni, E., Netto, G.J., Marchionni, L., et al., 2016]. Tissue-based genomics augments post-prostatectomy risk stratification in a natural history cohort of intermediate- and high-risk men. *Eur Urol* 69, 157–165.
- Zhao, S.G., Evans, J.R., Kothari, V., Sun, G., Larm, A., Mondine, V., et al., 2016]. The landscape of prognostic outlier genes in high-risk prostate cancer. *Clin Cancer Res* 22, 1777–1786.
- Jain, S., Lyons, C., Walker, S.M., Mcquaid, S., Hynes, S., Mitchell, D.M., et al., 2017]. A metastatic biology gene expression assay to predict the risk of distant metastases in patients with localized prostate cancer treated with primary radical treatment. *J Clin Oncol* 35, 11.
- Cunningham, D., You, Z., 2015]. *In Vitro and In Vivo Model Systems Used in Prostate Cancer Research*. p. 2015.
- Bibikova, M., Chudin, E., Arsanjani, A., Zhou, L., Garcia, E.W., Modder, J., et al., 2007]. Expression signatures that correlated with Gleason score and relapse in prostate cancer. *Genomics* 89, 666–672.
- Bismar, T.A., Demicheli, F., Riva, A., Kim, R., Varambally, S., He, L., et al., 2006]. Defining aggressive prostate cancer using a 12-gene model. *Neoplasia (New York, NY)* 8, 59–68.
- Cuzick, J., Swanson, G.P., Fisher, G., Brothman, A.R., Berney, D.M., Reid, J.E., et al., 2011]. Prognostic value of an RNA expression signature derived from cell cycle proliferation genes in patients with prostate cancer: a retrospective study. *Lancet Oncol* 12, 245–255.
- Glinsky, G.V., Glinskii, A.B., Stephenson, A.J., Hoffman, R.M., Gerald, W.L., 2004]. Gene expression profiling predicts clinical outcome of prostate cancer. *J Clin Invest* 113, 913–923.
- Irshad, S., Bansal, M., Castillo-Martin, M., Zheng, T., Aytes, A., Wenske, S., et al., 2013]. A molecular signature predictive of indolent prostate cancer. *Sci Transl Med* 5 (202ra122–202ra122).
- Knezevic, D., Goddard, A.D., Natraj, N., Cherbavaz, D.B., Clark-Langone, K.M., Snable, J., et al., 2013]. Analytical validation of the Oncotype DX prostate cancer assay – a clinical RT-PCR assay optimized for prostate needle biopsies. *BMC Genomics* 14, 690.
- Long, Q., Johnson, B.A., Osunkoya, A.O., Lai, Y.-H., Zhou, W., Abramovitz, M., et al., 2011]. Protein-coding and MicroRNA biomarkers of recurrence of prostate cancer following radical prostatectomy. *Am J Pathol* 179, 46–54.
- Singh, D., Febbo, P.G., Ross, K., Jackson, D.G., Manola, J., Ladd, C., et al., 2002]. Gene expression correlates of clinical prostate cancer behavior. *Cancer Cell* 1, 203–209.
- Stephenson, A.J., Smith, A., Kattan, M.W., Satagopan, J., Reuter, V.E., Scardino, P. T., et al., 2005]. Integration of gene expression profiling and clinical variables to predict prostate carcinoma recurrence after radical prostatectomy. *Cancer* 104, 290–298.
- Wu, C.-L., Schroeder, B.E., Ma, X.-J., Cutie, C.J., Wu, S., Salunga, R., et al., 2013]. Development and validation of a 32-gene prognostic index for prostate cancer progression. *Proc Natl Acad Sci* 110, 6121–6126.
- Yu, J., Yu, J., Rhodes, D.R., Tomlins, S.A., Cao, X., Chen, G., et al., 2007]. A polycomb repression signature in metastatic prostate cancer predicts cancer outcome. *Cancer Res* 67, 10657–10663.
- Lalonde, E., Alkallas, R., Chua, M. L. K., Fraser, M., Haider, S., Meng, A., Zheng, J., Yao, C. Q., Picard, V., Orain, M., Hovington, H., Murgic, J., Berlin, A., Lacombe, L., Bergeron, A., Fradet, Y., Têtu, B., Lindberg, J., Egevad, L., Grönberg, H., Ross-Adams, H., Lamb, A. D., Halim, S., Dunning, M. J., Neal, D. E., Pintilie, M., VAN DER Kwast, T., Bristow, R. G. & Boutros, P. C. 2017. Translating a prognostic DNA genomic classifier into the clinic: retrospective validation in 563 localized prostate tumors. *Eur Urol*
- Gardner, L.B., Li, Q., Park, M.S., Flanagan, W.M., Semenza, G.L., Dang, C.V., 2001]. Hypoxia inhibits G1/S transition through regulation of p27 expression. *J Biol Chem* 276, 7919–7926.
- Guillaumond, F., Leca, J., Olivares, O., Lavaut, M.-N., Vidal, N., Berthezène, P., et al., 2013]. Strengthened glycolysis under hypoxia supports tumor symbiosis and hexosamine biosynthesis in pancreatic adenocarcinoma. *Proc Natl Acad Sci* 110, 3919–3924.
- Spratt, D.E., Yousefi, K., Dehesi, S., Ross, A.E., Den, R.B., Schaeffer, E.M., et al., 2017]. Individual patient-level meta-analysis of the performance of the decipher genomic classifier in high-risk men after prostatectomy to predict development of metastatic disease. *J Clin Oncol* 35, 1991–1998.
- Hieronymus, H., Schultz, N., Gopalan, A., Carver, B.S., Chang, M.T., Xiao, Y., et al., 2014]. Copy number alteration burden predicts prostate cancer relapse. *Proc Natl Acad Sci U S A* 111, 11139–11144.

- [50] Hall, J.S., Taylor, J., Valentine, H.R., Irlam, J.J., Eustace, A., Hoskin, P.J., et al., 2012]. Enhanced stability of microRNA expression facilitates classification of FFPE tumour samples exhibiting near total mRNA degradation. *Br J Cancer* 107, 684–694.
- [51] Mujcic, H., Rzymiski, T., Rouschop, K.M.A., Koritzinsky, M., Milani, M., Harris, A.L., et al., 2009]. Hypoxic activation of the unfolded protein response (UPR) induces expression of the metastasis-associated gene LAMP3. *Radiother Oncol* 92, 450–459.
- [52] Mckeown, S.R., 2014]. Defining normoxia, physoxia and hypoxia in tumours—implications for treatment response. *Br J Radiol* 87, 20130676.
- [53] Chi, J.-T., Wang, Z., Nuyten, D.S.A., Rodriguez, E.H., Schaner, M.E., Salim, A., et al., 2006]. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. *PLoS Med* 3, e47.